Genprex, Inc. (GNPX) |
| 1.15 -0.15 (-11.54%) 04-10 16:00 |
| Open: | 1.3 |
| High: | 1.335 |
| Low: | 1.15 |
| Volume: | 604,924 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.07 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.12 |
| Resistance 1: | 1.75 |
| Pivot price: | 1.64 |
| Support 1: | 1.15 |
| Support 2: | 0.96 |
| 52w High: | 55 |
| 52w Low: | 1.15 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Financials
| EPS | -16330000.000 |
| Book Value | 261.620 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -273.3 |
| Return on Equity (ttm) | -1.0 |
Company news
Wed, 18 Mar 2026
Genprex collaborators to present lung cancer data at AACR meeting - Investing.com
Tue, 10 Mar 2026
Genprex brings gene therapies to 3,700-strong Lisbon biotech event - Stock Titan
Mon, 23 Feb 2026
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Yahoo Finance
Mon, 23 Feb 2026
Genprex stock jumps on Japan, Europe patent approvals - Investing.com
Thu, 15 Jan 2026
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Fri, 09 Jan 2026
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Sahm
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
